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On average, one in four adults has hypertension.1 This figure is higher in certain regions of the world, and in certain areas within 
countries. Worldwide, however, the prevalence of hypertension is on the rise. The relationship between level of blood pressure and 
risk for cardiovascular events is linear and continuous.
Nearly 75% of adults with other cardiovascular disease have hypertension as a comorbidity. Hypertension is associated with 
shorter overall life expectancy, as well as a shorter life expectancy free of cardiovascular disease.
Hypertension can be said to be controlled or at goal if blood pressure is less than 140/90 mmHg, or less than 130/80 mmHg for 
those with diabetes, kidney disease or a previous vascular event (e.g. myocardial infarction, stroke, etc). 
	 SA	Fam	Pract	2010;52(5):417-421
Blood pressure control
Not achieving optimal blood pressure control is one of the most 
common attributable risks for death worldwide. Despite the 
proven benefits of hypertension treatment in improving mortality 
and morbidity, the treatment and control of hypertension 
remain less than optimal. In many clinical trials, the message 
and concept became clear: reduction of blood pressure is the 
key driver of benefit in hypertension management. 
All five major antihypertension classes of drugs, diuretics, 
calcium channel blockers, angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs) and 
beta-blockers (maybe not to be used as single first-line agents) 
are of benefit by reducing events, and do not differ significantly 
in their overall ability to reduce blood pressure in hypertension. 
In numerous clinical trials, the control of blood pressure is 
achieved in only about half the time with monotherapy, even 
under strict trial conditions. 
Concept of combination therapy
Combination therapy with two or more drugs will be necessary 
in the majority of hypertensive patients to achieve target blood 
pressure. Combination therapy will even be more frequently 
needed in diabetics and other high risk patients to reach the 
stricter goal blood pressure in these patients. Different classes 
of antihypertensive agents, when combined, often have greater 
antihypertensive effect than each on its own (synergistic effect) 
and may have better tolerability (two components minimising 
each other’s side effects).
Despite this, the majority of trials of blood pressure lowering 
have focused on initial treatment with monotherapy.
Combination therapy: when to initiate?
Guidelines on hypertension, recommend that combination	
treatment	 be	 initiated	 as	 first-line	 therapy	 when there is 
a high cardiovascular risk: when the initial blood pressure is 
more than 20 mmHg systolic and 10 mmHg diastolic above the 
target (goal) blood pressure, when there is subclinical organ 
damage (diabetes, renal, cardiovascular disease).2 The choice 
between initiating monotherapy or combination therapy is often 
based more on wisdom and experience than trial evidence. 
Combination therapy will also be initiated when monotherapy 
fails.
Preferred drug combinations3
An ACE-inhibitor plus a calcium channel blocker was the 
most widely used combination in Syst-Eur, Syst-China, the 
HOT study, Invest (nondihydropyridine), and the ASCOT trial. 
In ACCOMPLISH, the combination of an ACE-inhibitor and 
a dihydropyridine calcium channel blocker outperformed the 
combination of the same ACE-inhibitor and a diuretic (thiazide) 
in reducing events. Whether this combination will always, under 
all circumstances be the best, remains to be seen in trials.
An ACE-inhibitor plus a diuretic have been used for many 
years. An ACE-inhibitor plus indapamide was highly successful 
in PROGRESS (previous stroke), ADVANCE (diabetes) and 
HYVET (elderly).
An ARB with a diuretic or calcium channel blocker has been 
used in the LIFE and SCOPE trials and demonstrated a 
protective effect. 
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More than one line of evidence is emerging that an ARB plus 
a calcium channel blocker or diuretic provides effective blood 
pressure reduction, a high rate of blood pressure control with a 
better tolerability profile.
Calcium channel blockers with a diuretic or beta-blocker have 
been used in the FEVER, ELSA and VALUE trials, with great 
benefit. 
The addition of an aldosterone antagonist (in low dose: 25 mg 
to 50 mg daily) to a drug regimen in resistant hypertension is 
often effective.
It is important to realise that there is no single optimal treatment 
for everyone with hypertension. When combinations of drugs 
are necessary to control blood pressure, physicians need to 
have choices.
Fixed dose (single pill) combinations
It was shown that a fixed combination pill, by reducing the 
number of pills to be taken, improves compliance significantly.4 
The availability of different fixed dose combinations of the 
same two drugs facilitates better titration. Fixed low-dose 
combinations are available (e.g. low-dose thiazide plus a low-
dose “newer” beta-blocker) and are increasingly released on 
the market, which contributes to simplicity of administration 
and reduced side effects. However, much more data are 
needed on fixed-dose combinations as preferred agents.
Which combination is potentially unwise?
It is prudent not to use a nondihydropyridine plus a beta-
blocker, due to excessive heart rate reduction. 
The older type of beta-blocker/diuretic combination in high 
doses favours the development of diabetes and should be 
avoided (especially in the young and obese individuals).
The combination of an ACE-inhibitor with an ARB has no 
proven benefit and could lead to more side effects.
Conclusion 
New and old evidence strongly supports combination treatment 
as the most effective way to control blood pressure.
There are a number of likely combinations of drug therapy for 
hypertension from which the physician can choose. Currently, 
renin-angiotensin system blockade combined with a calcium 
channel blocker or a diuretic are commonly used.
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Systolic Hypertension in Europe 
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1997;350:757-64.
Designed to investigate whether active treatment of isolated systolic hypertension, which 
occurs in 15% of people 60 years or older, could reduce cardiovascular complications. 
All patients were initially administered placebo. After stratification, 4 695 patients were 
randomly assigned to nitrendipine 10-40 mg daily, with possible enalapril 5-20 mg and 
hydrochlorothiazide 12.5-25 mg, or placebo. Patients withdrawing from treatment were 
followed up. 
Antihypertensive drug treatment, starting 
with nitrendipine, reduces the rate of 
cardiovascular complications among 
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L. Chinese trial on isolated systolic 
hypertension in the elderly. Systolic 
Hypertension in China (Syst-China) 
Collaborative Group. Arch Intern 
Med. 2000;160:211-20. 
Designed to explore how the benefits of active treatment of isolated systolic hypertension 
were distributed across patient groups according to gender and previous cardiovascular 
complications, and whether the morbidity and mortality results were influenced by age, 
level of systolic or diastolic blood pressure, smoking or drinking habits, or diabetes mellitus. 
Patients 60 years or older (systolic BP 160-219 mm Hg, diastolic BP < 95 mm Hg were 
enrolled. 1 253 patients were assigned to active treatment (initial nitrendipine, 10-40 mg, 
with possible captopril, 12.5-50 mg, and/or hydrochlorothiazide, 12.5-50 mg). 1 141 control 
patients received placebo. 
In elderly Chinese patients with isolated 
systolic hypertension, stepwise 
antihypertensive drug treatment 
improved prognosis. The benefit 
was particularly evident in diabetic 
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aspirin in patients with hypertension: 
principal results of the Hypertension 
Optimal Treatment (HOT) 
randomised trial. HOT Study Group. 
Lancet. 1998;351:1755-1762.
There is often a higher incidence of cardiovascular complications in hypertensive patients 
on treatment than in normotensive individuals, possibly as a result of inadequate reduction 
of blood pressure. The investigators aimed to assess the optimum target diastolic blood 
pressure, and the potential benefit of a low dose of aspirin in the treatment of hypertension. 
18 790 patients, aged 50-80 years with hypertension and diastolic blood pressure of 100-115 
mmHg (mean 105 mmHg) were randomly assigned a target diastolic blood pressure. 6264 
patients were allocated the target of < 90 mmHg, 6 264 < 85 mmHg, and 6 262 < 80 mmHg. 
Felodipine was given as baseline therapy with the addition of other agents, according to a 
five-step regimen. In addition, 9 399 patients were randomly assigned 75 mg/day aspirin and 
9 391 patients were assigned placebo.
Intensive lowering of blood pressure 
was associated with a low rate of 
cardiovascular events, with benefits 
when the diastolic blood pressure was 
lowered 82.6 mmHg. Aspirin significantly 
reduced major cardiovascular events, 
particularly myocardial infarction. There 
was no effect on the incidence of stroke 
or fatal bleeds, but non-fatal major 
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design of the International Verapamil 
SR/Trandolapril Study (INVEST): 
an internet-based randomized trial 
in coronary artery disease patients 
with hypertension. J Am Coll 
Cardiol. 1998;32:1228-37.
In this randomised, open label, blinded end point study, 22 576 hypertensive patients (> 
50 years) with coronary artery disease were randomly assigned to one of two arms, CAS 
(verapamil sustained release) or NCAS (atenolol). Trandolapril and/or hydrochlorothiazide 
were administered to achieve blood pressure goals of < 140 mmHg (systolic) and < 90 
mmHg (diastolic); and < 130 mmHg (systolic) and < 85 mmHg (diastolic) if diabetes or renal 
impairment was present. Trandolapril was also recommended for patients with heart failure, 
diabetes, or renal impairment.
The verapamil-trandolapril-based 
treatment was as clinically effective as 
the atenolol-hydrochlorothiazide-based 
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in the Anglo-Scandinavian Cardiac 
Outcomes Trial-Blood Pressure 
Lowering Arm (ASCOT-BPLA): a 
multicentre randomised controlled 
trial. Lancet. 2005;366:895–906.
The failure to prevent coronary heart disease observed in early hypertension trials has been 
attributed to the disadvantages associated with the use of diuretics and beta blockers. 
It was suggested that newer drugs would confer advantages. The aim was to compare 
the effect, on non-fatal myocardial infarction and fatal coronary heart disease, of atenolol 
plus a thiazide versus amlodipine plus perindopril. This was a multicentre, prospective, 
randomised controlled trial in 19 257 hypertensive patients, aged 40-79 years, with at least 
three other cardiovascular risk factors. Patients were assigned either amlodipine 5-10 mg 
plus perindopril 4-8 mg as required (n=9 639) or atenolol 50-100 mg plus bendroflumethiazide 
1.25-2.5 mg and potassium as required (n=9 618). The primary endpoint was non-fatal 
myocardial infarction and fatal coronary heart disease. 
Amlodipine-based therapy prevented 
more major cardiovascular events and 
induced less diabetes than atenolol-
based therapy.
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et al. or Benazepril plus amlodipine 
or hydrochlorothiazide for 
hypertension in high-risk patients. N 
Engl J Med. 2008;359:2417-2428.
The investigators hypothesised that treatment with an ACE inhibitor combined with a 
dihydropyridine calcium channel blocker would reduce the rate of cardiovascular events more 
effectively than treatment with an ACE inhibitor plus a thiazide diuretic. 11 506 hypertensive 
patients at high risk for cardiovascular events were randomised to receive benazepril 
plus amlodipine, or benazepril plus hydrochlorothiazide. The primary end point was the 
composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal 
stroke, hospitalisation for angina, resuscitation after sudden cardiac arrest, and coronary 
revascularisation.
Benazepril-amlodipine was superior 
to benazepril-hydrochlorothiazide in 
reducing cardiovascular events in 






PROGRESS Collaborative Group. 
Randomised trial of a perindopril-
based blood-pressure-lowering 
regimen among 6,105 individuals 
with previous stroke or transient 
ischaemic attack. Lancet. 
2001;358:1033-1041.
This study was designed to determine the effects of a blood pressure-lowering regimen in 
hypertensive and non-hypertensive patients with a history of stroke or transient ischaemic 
attack. 6 105 individuals were randomly assigned active treatment (3 051) or placebo (3 054). 
Active treatment consisted of a regimen based on perindopril (4 mg), with the addition of the 
diuretic indapamide at the discretion of treating physicians. The primary outcome was total 
stroke (fatal or non-fatal). 
The regimen reduced the risk of stroke 
among both hypertensive and non-
hypertensive individuals with a history 
of stroke or transient ischaemic attack. 
Combination therapy with perindopril 
and indapamide produced larger blood 
pressure and risk reductions.






ADVANCE Collaborative Group. 
Effects of a fixed combination of 
perindopril and indapamide on 
macrovascular and microvascular 
outcomes in patients with type 2 
diabetes mellitus (the ADVANCE 
trial): a randomised controlled trial. 
Lancet. 2007;370:829-840.
This trial assessed the effects of the routine administration of an ACE inhibitor-diuretic 
combination on serious vascular events in patients with diabetes, irrespective of initial blood 
pressure levels or the use of other antihypertensives. 11 140 patients with type 2 diabetes 
received either a combination of perindopril and indapamide or placebo, in addition to current 
therapy. The primary end points were composites of major macrovascular and microvascular 
events, defined as death from cardiovascular disease, non-fatal stroke or non-fatal 
myocardial infarction, and new or worsening renal or diabetic eye disease.
Routine administration of perindopril 
and indapamide to patients with type 2 
diabetes was well tolerated and reduced 
the risks of major vascular events, 
including death.
HYVET Hypertension in 
the Very Elderly 
Trial
Beckett NS, Peters R, Fletcher AE; 
HYVET Study Group. Treatment of 
hypertension in patients 80 years 
of age or older. N Engl J Med. 
2008;358:1887-1898.
It was unclear whether there is any benefit in the treatment of patients with hypertension 
who are 80 years or older; antihypertensive therapy may reduce the risk of stroke, but could 
possibly increase the risk of death. 3 845 hypertensive patients, 80 years or older,  were 
randomised to receive either indapamide (sustained release, 1.5 mg) or placebo. Perindopril 
(2 or 4 mg), or placebo, was added if necessary to achieve the target blood pressure of 
150/80 mmHg. The primary end point was fatal or non-fatal stroke.
Antihypertensive treatment with 
indapamide (sustained release), with or 
without perindopril, in persons 80 years 







Dahlöf B, Devereux RB, Kjeldsen 
SE, et al; LIFE Study Group. 
Cardiovascular morbidity 
and mortality in the Losartan 
Intervention For Endpoint reduction 
in hypertension study (LIFE): a 
randomised trial against atenolol. 
Lancet. 2002;359:995-1003. 
Left ventricular hypertrophy is a good indicator of risk of cardiovascular morbidity and death. 
The investigators wanted to establish whether selective blocking of angiotensin II improves 
hypertrophy beyond reducing blood pressure, and if this reduces cardiovascular morbidity 
and death. 9 193 hypertensive participants, with left ventricular hypertrophy were assigned 
losartan-based or atenolol-based treatment for at least four years, until 1 040 patients had a 
primary cardiovascular event (death, myocardial infarction, stroke). 
Losartan prevents more cardiovascular 
morbidity and death than atenolol for a 
similar reduction in blood pressure, is 
better tolerated, and seems to confer 
benefits beyond reduction in blood 
pressure.
SCOPE Study on 
Cognition and 
Prognosis in the 
Elderly
Lithell H, Hansson L, Skoog I, et al: 
SCOPE Study Group. The Study 
on Cognition and Prognosis in the 
Elderly (SCOPE): principal results 
of a randomized double-blind 
intervention trial. J Hypertens. 
2003;21(5):875-886.
The objective was to assess whether candesartan-based antihypertensive treatment in 
elderly patients, with mild to moderate hypertension, causes a reduction in cardiovascular 
events, cognitive decline and dementia. 4 964 patients, aged 70-89 years, were assigned 
randomly to receive candesartan or placebo, with open-label antihypertensive therapy added 
on if needed. The primary outcome measure was a composite of cardiovascular death, non-
fatal stroke and non-fatal myocardial infarction, and secondary outcome measures included 
cardiovascular death, stroke and myocardial infarction, cognitive function and dementia.
A slightly more effective blood 
pressure reduction with candesartan-
based therapy was associated with a 
statistically non-significant reduction in 
major cardiovascular events and with 
a marked reduction in non-fatal stroke. 
Cognitive function was well maintained 
in both treatment groups. Both treatment 
regimens were generally well tolerated.
FEVER Felodipine Event 
Reduction
Liu L, Zhang Y, Liu G, et al; FEVER 
Study Group. The Felodipine 
Event Reduction (FEVER) 
Study: a randomized long-term 
placebo-controlled trial in Chinese 
hypertensive patients. J Hypertens. 
2005;23(12):2157-2172.
The study was designed to compare the incidence of stroke and other cardiovascular events 
in patients receiving a low-dose diuretic and a low-dose calcium antagonist combination, 
with those on low-dose diuretic monotherapy, and assess the effects of a small blood 
pressure difference at levels lower than those achieved in previous trials. 9 800 Chinese 
hypertension patients, with additional cardiovascular risk factors/disease, were enrolled. Six 
weeks after switching to low-dose (12.5 mg) hydrochlorothiazide, if their blood pressure was 
in the range 140-180 mmHg (systolic) or 90-100 mmHg (diastolic), they were assigned to low-
dose felodipine extended release or placebo, and followed up for 40 months.
In these moderately complicated 
patients, a difference in SBP/DBP as 
small as 4/2 mmHg is associated with 






Zanchetti A, Bond MG, Hennig M, 
et al; European Lacidipine Study 
on Atherosclerosis investigators. 
Calcium antagonist lacidipine slows 
down progression of asymptomatic 
carotid atherosclerosis: principal 
results of the European Lacidipine 
Study on Atherosclerosis (ELSA), 
a randomized, double-blind, 
long-term trial. Circulation. 
2002;106:2422-2427.  
Usually, the cardiovascular complications of hypertension arise as a result of atherosclerosis. 
Some antihypertensive agents influence atherosclerosis independently of blood pressure 
lowering. This trial in 2 334 patients with hypertension compared the effects of four-year 
treatment with either lacidipine or atenolol on an index of carotid atherosclerosis, the mean 
of the maximum intima media thicknesses. This index has been shown by epidemiological 
studies to be predictive of cardiovascular events.
The greater efficacy of lacidipine 
on carotid intima media thickness 
progression and number of plaques per 
patient, despite a smaller ambulatory 
blood pressure reduction, indicates an 






Julius S, Kjeldsen SE, Weber M, et 
al; VALUE trial group. Outcomes 
in hypertensive patients at high 
cardiovascular risk treated with 
regimens based on valsartan or 
amlodipine: the VALUE randomised 
trial. Lancet. 2004;363:2022-2031.
The trial was designed to test the hypothesis that, for the same blood pressure control, 
valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive 
patients at high cardiovascular risk. 15 245 patients, 50 years and older, with hypertension 
and high risk of cardiac events participated in a comparison of therapy based on valsartan 
or amlodipine. The trial lasted until at least 1 450 patients had reached a primary endpoint, a 
composite of cardiac mortality and morbidity. Patients were followed up for 4.2 years.
The main outcome of cardiac disease did 
not differ between the treatment groups. 
Unequal reductions in blood pressure 
might account for differences between 
the groups.
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